Anti-CALCA polyclonal antibody

A U-Pb zircon age of 1762 +/- 11 Ma is reported for granite gneiss located on Flinders Island, South Australia, This age is identical, within analytical uncertainty, to a previously reported age for schists of the Price Metasediments located 100 km to the southeast on the southwestern coast of the Eyre Peninsula. The outcrop represents the only known country rock to the Early Mesoproterozoic Calca Granite (Hiltaba Suite) of Flinders Island, the largest island of the Investigator Group of islands, in the southwestern Gawler Craton. The stratigraphic name Investigator Granite Gneiss is proposed for this rock unit. The discovery of the Investigator Granite Gneiss now considerably increases the extent of known Late Palaeoproterozoic rocks on the eastern side of the peninsula. The outcrop was previously included with the considerably younger St Peter Suite granite-monzogranite, and grouped together with other islands in the Investigator Group. This new dating suggests that the geology on the other islands may require revision, For the first time, detailed major and trace-element geochemistry is supplied for the granite gneiss on Flinders Island.

Testicular germ cell tumors (TGCT) represent the second main cause of cancer-related death in young men. Despite high cure rates, refractory disease results in poor prognosis. Epigenetic reprogramming occurs during the development of seminomas and non-seminomas. Understanding the molecular and genetic basis of these tumors would represent an important advance in the search for new TGCT molecular markers. Hence the frequency of methylation of a gene panel (VGF, MGMT, ADAMTS1, CALCA, HOXA9, CDKN2B, CDO1 and NANOG) was evaluated in 72 primary TGCT by quantitative methylation specific PCR. A high frequency of MGMT (90.9%, 20/22; p=0.019) and CALCA (90.5%, 19/21; p<0.026) methylation was associated with non-seminomatous tumors while CALCA methylation was also associated with refractory disease (47.4%, 09/19; p=0.005). Moreover, promoter methylation of both genes predicts poor clinical outcome for TGCT patients (5-year EFS: 50.5% vs 77.1%; p=0.032 for MGMT and 51.3% vs 77.0%; p=0.029 for CALCA). The findings of this study indicate that methylation of MGMT and CALCA are frequent and could be used as new molecular markers of prognosis in TGCT.